Key Developments For Affymax, Inc.
Affymax, Inc. (AFFY.O) (Consolidated Issue listed on NASDAQ Global Market)
Affymax, Inc. Announces Close of Common Stock Offering
Affymax, Inc. announced the closing of its underwritten public offering of 4,726,027 shares of its common stock, which includes the full exercise of the underwriter`s overallotment option of 616,438 shares. The net proceeds to the Company after deducting underwriting discounts and commissions and estimated offering expenses are approximately $80.0 million. Cowen and Company, LLC and Lazard Capital Markets LLC were joint book runners on the offering.
Affymax, Inc. Prices Public Offering of Common Stock
Affymax, Inc. announced that it has priced an underwritten public offering of 4,109,589 shares of its common stock at a price of $18.25 per share. Net proceeds, after estimated underwriting discounts and commissions and estimated expenses, will be approximately $69.6 million. Affymax has granted the underwriters a thirty day option to purchase up to 616,438 additional shares of common stock to cover over allotments, if any. The offering is expected to close on or about November 24, 2009. Cowen and Company, LLC and Lazard Capital Markets LLC are acting as joint book runners, with RBC Capital Markets Corporation and Robert W. Baird & Co. Incorporated acting as co-managers for the offering.
Affymax, Inc. Announces Proposed Public Offering of Common Stock
Affymax, Inc announced that it intends to offer, subject to market and other conditions, shares of its common stock in an underwritten public offering. The Company expects to grant the underwriters a thirty-day option to purchase additional shares of common stock to cover overallotments, if any. Cowen and Company, LLC and Lazard Capital Markets LLC are acting as joint book-runners, with RBC Capital Markets Corporation and Robert W. Baird & Co. Incorporated acting as co-managers for the offering.
Affymax, Inc. Announces Completion Of Final Scheduled Data Monitoring Committee Review Of Phase 3 Hematide Program
Affymax, Inc. announced that independent Data Monitoring Committee (DMC), which provides oversight for the Phase 3 program for Hematide, has completed its final scheduled review and has informed the company that the cumulative safety data generated thus far from the EMERALD and PEARL Phase 3 trials support continuation of the studies. While no additional meetings are planned, the DMC, under its charter, can request additional information regarding the studies at any time. In the Phase 3 program, Hematide is being evaluated to treat anemia in chronic renal failure patients on dialysis and not on dialysis. The Phase 3 program, which consists of four trials, was initiated in October 2007. Affymax reiterated its expectation for a NDA submission in 2010.
Affymax, Inc. Names Hollings C. Renton As Chairman
Affymax, Inc. announced the appointment of Hollings C. Renton to the position of Chairman of the Company's Board of Directors effective December 1, 2009. Mr. Renton replaces Nick Galakatos will be resigning his position as a member of the Board of Directors at the end of 2009. In addition to assuming the role of Chairman of the Board, Mr. Renton will also Chair the Company's Nominating and Governance Committee.
